Document is current
Any future updates will be listed below
-
Authors
Schwartz, Christopher J.
Genco, Iskender
Repetto, Matteo
Muldoon, Daniel
Gazzo, Andrea
Terraf, Panieh
Grabenstetter, Anne
Ross, Dara
Zhang, Hong
Mandelker, Diana
Powell, Simon
Weigelt, Britta
Bandlamudi, Chaitanya
Brogi, Edi
Pareja, Fresia
Wen, Hannah Y.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30-CA008748, P30-CA008748, P30-CA008748)
National Institutes of Health (CA247749-01, CA247749-01, CA247749-01)
Breast Cancer Research Foundation
U.S. Food and Drug Administration (1U01FD007909-01A1)
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 4 July 2025
First Online: 22 July 2025
Competing interests
: F.P. reports membership on the Scientific Advisory Board of MultiplexDx and has received consulting fees and served on advisory boards for AstraZeneca. BW reports research funding by Repare Therapeutics and SAGA Diagnostics paid to the institution, and employment of an immediate family member at AstraZeneca. All remaining authors declare no competing interests.
